Indivior (INDV) to Release Earnings on Thursday

by · The Markets Daily

Indivior (NASDAQ:INDV – Get Free Report) is expected to be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Indivior to post earnings of $0.65 per share and revenue of $305.62 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Indivior Stock Performance

NASDAQ INDV opened at $33.06 on Wednesday. The business has a fifty day moving average price of $34.68 and a 200 day moving average price of $29.87. The company has a market cap of $4.13 billion, a P/E ratio of 35.93 and a beta of 0.80. Indivior has a one year low of $7.62 and a one year high of $38.00.

Insider Activity at Indivior

In other Indivior news, Director Daniel A. Ninivaggi bought 775 shares of the business’s stock in a transaction on Monday, January 5th. The stock was bought at an average price of $35.39 per share, with a total value of $27,427.25. Following the completion of the purchase, the director directly owned 16,923 shares in the company, valued at $598,904.97. The trade was a 4.80% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Mark Stejbach purchased 775 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was acquired at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the purchase, the director owned 16,847 shares in the company, valued at approximately $596,215.33. The trade was a 4.82% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 4,871 shares of company stock valued at $172,385 over the last 90 days.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Raymond James Financial Inc. acquired a new stake in shares of Indivior during the second quarter valued at about $26,000. Quarry LP purchased a new position in shares of Indivior during the 3rd quarter worth approximately $26,000. Aquatic Capital Management LLC purchased a new position in shares of Indivior during the 3rd quarter worth approximately $104,000. California State Teachers Retirement System acquired a new stake in Indivior in the 2nd quarter valued at approximately $112,000. Finally, Tower Research Capital LLC TRC raised its position in Indivior by 851.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,567 shares of the company’s stock valued at $156,000 after purchasing an additional 9,456 shares during the period. Institutional investors and hedge funds own 60.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Zacks Research cut shares of Indivior from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 13th. Craig Hallum reaffirmed a “buy” rating and set a $41.00 price objective on shares of Indivior in a research note on Friday, October 31st. Morgan Stanley reiterated an “overweight” rating and issued a $36.00 price objective on shares of Indivior in a report on Wednesday, December 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Indivior in a report on Wednesday, January 28th. Finally, HC Wainwright upped their price target on Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Five analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $39.33.

Get Our Latest Stock Analysis on Indivior

About Indivior

(Get Free Report)

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.

Further Reading